Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8031
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor which is in Phase 3 clinical development that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also offers development of bempedoic acid in a fixed dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.

Esperion Therapeutics Inc (ESPR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Esperion Therapeutics Raises US$33 Million In Venture Financing 11
Esperion Therapeutics Raises US$1 Million In Venture Financing 13
Equity Offering 14
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18
Esperion Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$70 Million 20
Esperion Therapeutics Inc – Key Competitors 22
Esperion Therapeutics Inc – Key Employees 23
Esperion Therapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 02, 2018: Esperion provides Bempedoic Acid franchise development program updates; reports second quarter 2018 financial results 25
May 02, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results 28
Feb 20, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results 29
Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results 31
Aug 08, 2017: Esperion Reports Second Quarter 2017 Financial Results 33
May 04, 2017: Esperion Reports First Quarter 2017 Financial Results 34
May 04, 2017: Esperion Therapeutics Q1 net loss up 35
Feb 22, 2017: Esperion Reports Fourth Quarter and Full Year 2016 Financial Results 36
Corporate Communications 37
Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37
Legal and Regulatory 39
May 10, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics 39
May 07, 2018: Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics and Certain Officers – ESPR 40
Product Approvals 41
Jun 26, 2017: Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe 41
Clinical Trials 42
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 42
Aug 08, 2017: Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Esperion Therapeutics Raises US$33 Million In Venture Financing 11
Esperion Therapeutics Raises US$1 Million In Venture Financing 13
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 20
Esperion Therapeutics Inc, Key Competitors 22
Esperion Therapeutics Inc, Key Employees 23

List of Figures
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quad/Graphics, Inc.:企業の戦略・SWOT・財務分析
    Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Quad/Graphics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Nomura Holdings, Inc.:企業のM&A・事業提携・投資動向
    Nomura Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nomura Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Fresenius Medical Care AG & Co. KGaA:企業の戦略・SWOT・財務分析
    Fresenius Medical Care AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary Fresenius Medical Care AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Encision Inc (ECIA):企業の財務・戦略的SWOT分析
    Summary Encision Inc (Encision) is a medical device company that manufactures and markets surgical instruments. The company provides laparoscopic monopolar surgical instruments. Its product portfolio includes AEM burn protection systems, AEM instrumentation, cord adapter, inhibit adapter extension, …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dirui Industrial Co Ltd (300396):企業の財務・戦略的SWOT分析
    Summary Dirui Industrial Co Ltd (Dirui) is a provider of total laboratory solutions. The company designs, develops, manufactures, and markets diagnostic medical equipment, reagents, and clinical diagnostic reagents. Its products include chemistry analyzer, urine analyzer, hematology analyzer, fecal …
  • Mitsui E&S Holdings Co., Ltd. (7003):企業の財務・戦略的SWOT分析
    Mitsui E&S Holdings Co., Ltd. (7003) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Calpine Corporation (CPN):電力:M&Aディール及び事業提携情報
    Summary Calpine Corporation (Calpine) is an electric and natural gas utility. The company produces electricity and thermal energy from natural gas, geothermal, and solar sources. It uses natural gas-fired combustion and renewable geothermal conventional steam turbine technologies to generate energy. …
  • TD Ameritrade Holding Corp:企業の戦略・SWOT・財務分析
    TD Ameritrade Holding Corp - Strategy, SWOT and Corporate Finance Report Summary TD Ameritrade Holding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Alliance Data Systems Corp (ADS):企業の財務・戦略的SWOT分析
    Alliance Data Systems Corp (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • EQT Corporation:企業の戦略・SWOT・財務情報
    EQT Corporation - Strategy, SWOT and Corporate Finance Report Summary EQT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Venture Corporation Limited (V03):企業の財務・戦略的SWOT分析
    Venture Corporation Limited (V03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ygm Trading Ltd.
    Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Point Resources AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Point Resources AS (Point Resources) ,is engaged in developing, exploring and production of petroleum products. It explores and produces crude oil, gas and natural gas liquids (NGLs) through Ringhorne, Balder and Jotun fields. Point Resources also offers seismic surveys and drilling services …
  • ReCor Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary ReCor Medical Inc (ReCor Medical), a subsidiary of Otsuka Holdings Co Ltd, is a medical device company that designs and manufactures a proprietary ultrasound ablation system for performing renal denervation. The company develops paradise renal denervation system, a therapeutic non-focused ul …
  • California Pizza Kitchen, Inc.
    California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report Summary California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • TriVascular Inc:製品パイプライン分析
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …
  • Pinnacle Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pinnacle Biologics Inc (Pinnacle Biologics), a subsidiary of Concordia International Corp is a drug development company that develops and markets photodynamic therapy products. The company offers products such as OPTIGUIDE PI, ETHYOL PI, PHOTOFRIN PI, and DIOMED products, among others. Its O …
  • H2O Retailing Corporation:企業の戦略・SWOT・財務情報
    H2O Retailing Corporation - Strategy, SWOT and Corporate Finance Report Summary H2O Retailing Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆